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The role of ATM and 53BP1 as predictive
markers in cervical cancer
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Treatment of advanced-stage cervical cancers with (chemo)radiation causes cytotoxicity through induction of high levels of DNA
damage. Tumour cells respond to DNA damage by activation of the ‘DNA damage response’ (DDR), which induces DNA repair and may
counteract chemoradiation efficacy. Here, we investigated DDR components as potential therapeutic targets and verified the predictive
and prognostic value of DDR activation in patients with cervical cancer treated with (chemo)radiation. In a panel of cervical cancer cell
lines, inactivation of ataxia telangiectasia mutated (ATM) or its substrate p53-binding protein-1 (53BP1) clearly gave rise to cell cycle
defects in response to irradiation. Concordantly, clonogenic survival analysis revealed that ATM inhibition, but not 53BP1 depletion,
strongly radiosensitised cervical cancer cells. In contrast, ATM inhibition did not radiosensitise non-transformed epithelial cells or non-
transformed BJ fibroblasts. Interestingly, high levels of active ATM prior to irradiation were related with increased radioresistance. To
test whether active ATM in tumours prior to treatment also resulted in resistance to therapy, immunohistochemistry was performed on
tumour material of patients with advanced-stage cervical cancer (n5 375) treated with (chemo)radiation. High levels of
phosphorylated (p-)ATM [p5 0.006, hazard ratio (HR)5 1.817] were related to poor locoregional disease-free survival. Furthermore,
high levels of p-ATM predicted shorter disease-specific survival (p5 0.038, HR5 1.418). The presence of phosphorylated 53BP1 was
associated with p-ATM (p5 0.001, odds ratio5 2.206) but was not related to any clinicopathological features or survival. In
conclusion, both our in vitro and patient-related findings indicate a protective role for ATM in response to (chemo)radiation in cervical
cancer and point at ATM inhibition as a possible means to improve the efficacy of (chemo)radiation.
The standard of care for patients with advanced-stage cervical
cancer has shifted over the last decade from radiotherapy
alone to platinum-based chemoradiation.1 Despite the shift in
this curative treatment modality, 5-year survival is still
around 66%, which leaves ample room for improvement.2
Chemoradiation introduces high levels of DNA double-strand
breaks (DSBs), with the aim to induce cell death.3,4 At the
molecular level, cells respond to DNA breaks with the activa-
tion of a distinct pathway called the ‘DNA damage response’
(DDR). The DDR recognises DNA damage and subsequently
coordinates a cell cycle arrest with the initiation of DNA
repair.3,4 Counteracting the effects of the DDR might thus be
an attractive option to improve treatment results in patients
with advanced cervical cancer.
Central in the DDR is the ataxia telangiectasia-mutated
(ATM) kinase. ATM plays a key role in detecting DNA DSBs
and in coordinating DNA repair, cell cycle arrest and induc-
tion of apoptosis.4 When DNA DSBs are induced, ATM is
activated through autophosphorylation on serine 1981
(Ser1981) and subsequently phosphorylates numerous down-
stream substrates, including cell cycle regulators, DNA repair
factors and proteins involved in apoptosis.3,5,6 The
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importance of ATM is underscored by the observed increased
radiosensitivity and cancer incidence in patients with ataxia
telangiectasia (AT), bearing a mutation in the ATM gene.7
One prototypical ATM substrate is the gene product of
TP53-binding protein-1 (53BP1),8–11 originally identiﬁed as a
protein that binds p53.12 In response to DNA damage,
53BP1 is rapidly phosphorylated by ATM on multiple resi-
dues including serine 25 (Ser25) and serine 1778
(Ser1778).6,13,14 Phosphorylated 53BP1 localises to irradia-
tion-induced foci where it promotes the activation of p53
and Chk2 and mediates the recruitment of the repair factor
BRCA1.8–10 53BP1, like ATM, is also involved in the repair
of DNA breaks by promoting non-homologous end join-
ing.15,16 However, 53BP1 can also be detected on sites of ho-
mologous recombination and in addition inﬂuences this
error-free type of repair.17 Altogether, these ﬁndings explain
its important role in proper responses to DNA breaks, and
many of the cellular defects observed in AT were recapitu-
lated in 53BP1/ cells, including irradiation sensitivity,
growth retardation and cancer predisposition.18,19
The aim of our study was to investigate to which degree
cervical cancer cells depend on the DDR after irradiation.
For this purpose, we have analysed responses of a panel of
cervical cancer cell lines to ionising irradiation. We have sub-
sequently investigated the role of ATM and 53BP1 as poten-
tial targets for radiosensitising approaches in vitro. Finally,
we tested the predictive and prognostic properties of ATM
pathway activity in tumours in a large, well-documented and
consecutive series of patients with cervical cancer primarily
treated with (chemo)radiation.
Material and Methods
Cell-line studies
The human papillomavirus (HPV)-positive cervical cancer
cell lines HeLa, CaSki and SiHa (all p53 wt) as well as the
HPV-negative C33A cell line (mutant p53) were cultured in
DMEM:Ham’s F12 (1:1), supplemented with 10% of fetal calf
serum, 100 U/ml of penicillin and 100 lg/ml of streptomy-
cin. Human embryonic 293T kidney cells, non-transformed
human retinal pigment epithelial (RPE) cells and human BJ
foreskin ﬁbroblasts were cultured in DMEM, supplemented
with 10% of fetal calf serum, 100 U/ml of penicillin and 100
lg/ml of streptomycin. Authenticity of cell lines was veriﬁed
by DNA short-tandem repeat analysis (Baseclear, Leiden, The
Netherlands). If indicated, cells were irradiated using a CIS
International/IBL 637 equipped with a cesium137 source
(0.01083 Gy/s). If indicated, cells were incubated with 10 lM
of ATM inhibitor KU55399 (Tocris Biosciences, Bristol,
United Kingdom).
RNA interference
Short-hairpin RNA sequences against the human TP53BP1
gene were previously described and validated.20 To produce
VSV-G pseudotyped retrovirus particles, 293T cells were
transfected with pRetrosuper (pRS), pRS-53BP1#1 (targeting
sequence 50-GAACGAGGAGACGGTAATA-30) or pRS-
53BP1#2 (50-GATACTGCCTCATCACAGT-30) and with the
packaging plasmids pMDG/P and pMDG in a 3:2:1 ratio
using a calcium phosphate protocol. Virus-containing super-
natant culture medium was ﬁltered (0.22 lm; Millipore, Bill-
erica, MA), mixed with polybrene (4 lg/ml) and used for
infection for three consecutive 12-hr periods. Twenty-four
hours after the third infection, puromycin was added (1 lg/
ml) for selection.
Western blotting and immunofluorescence
For Western blotting, cell lysates were obtained using Mam-
malian Protein Extraction Reagent (Thermo Scientiﬁc, Rock-
ford, IL), supplemented with protease inhibitor and phospha-
tases inhibitor cocktail (Thermo Scientiﬁc, Etten-Leur, The
Netherlands). Thirty micrograms of protein was used for
SDS-PAGE. Separated proteins were transferred to Polyviny-
lidene ﬂuoride membranes and blocked in 5% milk in tris-
buffered saline-0.01% Tween20. Immunodetection was done
with antibodies directed against 53BP1 (rabbit, H-300; Santa
Cruz Biotechnology, Santa Cruz, CA), MDM-2 (mouse, AB1;
Merck (Calbiochem), Darmstadt, Germany), phospho-Thr68-
Chk2 (rabbit, C13C1; Cell Signaling Technology, Danvers,
MA), p21 (Merck (Calbiochem), Darmstadt, Germany), b-
actin (mouse, A5441; Sigma-Aldrich, St. Louis, MO) and
phospho-Ser1981-ATM (rabbit, EP1890Y; Epitomics, Burlin-
game, CA). horseradish peroxidase-conjugated antibodies
(DAKO Denmark A/S, Glostrup, Denmark) were used as sec-
ondary antibodies. Visualisation was performed using
Enhanced Chemiluminescence (Lumilight, Roche diagnostics,
Mannheim, Germany) and a Biorad Bioluminescence device,
equipped with Quantity One/Chemidoc XRS software (Bio-
rad, Veenendaal, The Netherlands).
For immunoﬂuorescence, cells were grown on glass cover
slips. One hour after treatment, cells were ﬁxed in 3.7% formal-
dehyde, blocked in 5% bovine serum albumin and stained over-
night using anti-53BP1 (rabbit, H-300; Santa Cruz Biotechnol-
ogy, Santa Cruz, CA) and anti-c-H2AX (mouse, phospho-
Ser139, #05-636; Millipore, Billerica, MA). Cells were counter-
stained with Alexa-488- and Alexa-568-conjugated secondary
antibodies (Invitrogen (Molecular Probes), Eugene, OR) and
40,6-diamidino-2-phenylindole (Sigma-Aldrich, St. Louis, MO).
Clonogenic survival assays
Depending on the amount of irradiation, cells were seeded at
100 (0 Gy), 500 (2 Gy), 2,000 (4 Gy) or 5,000 cells per well
(6 Gy) in six-well plates and allowed to adhere for 4 hr. Cells
were subsequently irradiated at indicated doses. If indicated,
cells were pre-treated with ATM inhibitor (KU55933, 10 lM)
for 30 min. ATM inhibitor (KU55933)-treated CaSki cells
were seeded up to 80,000 cells per well due to extreme irradi-
ation sensitivity observed in initial experiments. When colony
size reached an approximate minimum size of 50 cells per
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colony after 10–14 days, cells were ﬁxed and stained using
methanol/acetic acid/water mixture (50, 20 and 30%, respec-
tively), containing 0.01% Coomassie brilliant blue. Surviving
fraction was calculated using the plating efﬁciencies, using
the non-irradiated controls as a reference. Results shown are
averages of three independent experiments performed in
triplicate.
Apoptosis assays and proliferation measurements
Twenty-four hours after plating in six-well plates, cells were
irradiated (10 Gy). If indicated, cells were pre-treated with
ATM inhibitor (KU55933, 10 lM) for 30 min. Twenty-four
hours after irradiation, apoptosis was assessed visually by ﬂu-
orescence microscopy after staining nuclear chromatin with
acridine orange. Apoptosis assays were independently per-
formed in triplicate. To measure cell proliferation, 7,000
HeLa cells or SiHa cells were plated in 96-well plates in the
presence or absence of KU55933 (10 lM). Directly after
plating, or at 24, 48 or 72 hr after plating, 20 ll of 5 mg/ml
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) was added for 2 hr. Subsequently, culture medium
was removed, and then the cells were incubated in dimethyl
sulphoxide for 30 min. Absorbance was measured at 520 nm
using a Biorad microplate reader. Cell growth was measured
by calculating relative increases of MTT conversion. MTT
conversion at Day 1 of plating was used as a reference.
Flow cytometry
Cells were harvested at indicated time points after irradiation
and ﬁxed in ice-cold 70% ethanol. Cells were stained with
rabbit anti-phospho-Ser10-Histone H3 antibody (rabbit, Cell
Signaling Technology, Danvers, MA, #06570, 1:200) and sub-
sequently stained with Alexa-488-conjugated anti-rabbit anti-
body (Invitrogen (Molecular Probes), Eugene, OR) and coun-
terstained with propidium iodide/RNAse (Sigma-Aldrich, St.
Louis, MO). Cell cycle distribution and phospho-Histone H3
positivity were analysed on a FACSCalibur (Becton Dickin-
son Biosciences, Franklin Lakes, NJ) equipped with CellQuest
software. Per sample, at least 1  104 events were analysed,
and indicated results show averages and standard deviations
of three independent experiments.
Patients with cervical cancer
Immunohistochemical analysis was performed on pre-treat-
ment tissue specimens of 375 patients with advanced-stage
cervical cancer primarily treated with chemoradiation, col-
lected between January 1980 and December 2006. Tissue
specimens were used to generate a tissue microarray as
described previously.21,22 Clinicopathological data of patients,
analysed in this study, are summarised in Supporting Infor-
mation Table S1. The mean follow-up time was 3.99 years
(range: 0.1–18.3) for all patients. For patients who were still
alive at the time of their ﬁnal follow-up, the median follow-
up time was 6.3 years. About 189 patients (50.4%) received
only radiotherapy, whereas 186 (49.6%) patients received che-
moradiation. Patients who received chemoradiation were
younger compared to patients who received radiotherapy
alone (median 46.8 vs. 64.8, p < 0.001). All other baseline
characteristics were comparable in both groups (data not
shown). Immunohistochemistry was performed with antibod-
ies against phospho-Ser1981-ATM (rabbit, EP1890Y, S1981;
Epitomics, Burlingame, CA), 53BP1 (rabbit, H-300, SC-
22760; Santa Cruz Biotechnology, Santa Cruz, CA), phospho-
Ser25-53BP1 (rabbit, AB82559; Abcam, Cambridge, United
Kingdom) and anti-c-H2AX (mouse, #05-636; Millipore,
Amsterdam, The Netherlands). As chemoradiation is associ-
ated with a better survival and is a time-dependent factor, we
adjusted for treatment modality in the multivariate analyses.
Additional detailed information about staining protocols,
patient information, evaluation of stainings and statistical
analysis can be found in the Supporting Information Docu-
ment SD1.
Results
ATM- and 53BP1-dependent cell cycle arrest in response
to irradiation
We investigated the role of ATM and 53BP1 in the cellular
response to irradiation in cervical cancer cells. To study cell
cycle arrest in G1 and G2 (a distinct early feature of the
DDR), different doses of irradiation were tested for their abil-
ity to induce cell cycle arrest and foci formation of 53BP1
and c-H2AX (Supporting Information Figs. S1A–S1D). To
subsequently study the role of ATM and 53BP1 in these
responses, we used chemical inhibition of ATM (KU55933)23
or interfered with the expression of 53BP1 using shRNA
(Fig. 1a) in our panel of HPV-positive (SiHa, HeLa and
CaSki) cell lines and the HPV-negative C33A cell line (har-
bouring a p53 mutant). Cell lines stably expressing 53BP1
shRNAs as well as cell lines in which ATM was inactivated
showed normal proliferation compared to their control coun-
terparts (Fig. 1b). Upon irradiation (5 Gy), clear cell cycle
arrests in G1 and G2 were observed (Figs. 1b, 1d and 1e).
Interestingly, ATM inhibition or 53BP1 depletion completely
ablated the G1 arrest in response to irradiation in all exam-
ined HPV-positive cell lines (Figs. 1b and 1d). Similar results
were obtained when we used a second shRNA against 53BP1
(Supporting Information Figs. S2A–S2C). These results indi-
cate that both ATM and 53BP1 are required for the irradia-
tion-induced G1 arrest in HPV-positive cervical cancer cell
lines. The p53-mutant cell line C33A did not show a signiﬁ-
cant irradiation-induced G1 arrest (Fig. 1d), which is in line
with the p53-dependent G1 arrest after irradiation.
24,25
Indeed, neither ATM inhibition nor 53BP1 depletion further
changed the proportion of G1 cells in C33A cells (Fig. 1d).
We next investigated the ability of cervical cancer cells to
arrest at the G2/M border. G2/M checkpoint activity was
measured by the number of cells that enters mitosis after
irradiation, judged by phospho-HistoneH3-positivity. Shortly
after irradiation, control cells showed a clear decrease in the
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percentage of mitotic cells, as expected from cells with an
intact G2/M checkpoint (Figs. 1b and 1e). Notably, ATM in-
hibition resulted in failure to properly arrest cells at the G2/
M border after irradiation (Figs. 1b and 1e). In sharp con-
trast, cells depleted of 53BP1 still exhibited a clear decrease
in mitotic cells upon irradiation comparable to that of irradi-
ated control cells (Figs. 1b and 1e). These results indicate
that ATM, but not 53BP1, is required for a proper G2/M
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arrest in response to irradiation, and furthermore, these
results show that the G1 and the G2/M arrests have different
molecular requirements in cervical cancer cells.
Although previous studies have attributed an irradiation
induced G1-arrest to p53 function,26 we still observed a promi-
nent G1-arrest in all HPV-positive cervical cancer cell lines, de-
spite the compromised p53 function in these cells. Therefore, we
tested p53 function and observed expression of p53-target genes
MDM2 and p21 in HeLa cells, albeit at low levels (Fig. 1c). Inter-
estingly, depletion of 53BP1 resulted in a virtually complete loss
of expression of MDM2 and p21, suggesting that the residual ac-
tivity of p53 in cervical cancer cells depends on 53BP1 (Fig. 1c).
Regarding ATM inhibition as a therapeutic option, we
compared the ability of ATM inhibition to induce apoptosis
in HeLa cells versus human non-transformed RPE cells and
human BJ foreskin ﬁbroblasts. Although ATM inhibition
clearly elevated the levels of apoptotic HeLa cells after irradi-
ation, non-transformed RPE cells or BJ foreskin ﬁbroblasts
did not show any signiﬁcant elevation of apoptosis levels in
response to combined treatment with KU55933 and irradia-
tion (Fig. 1f and Supporting Information Fig. S1E).
ATM, but not 53BP1, is required for clonogenic survival
after irradiation
Our cell cycle analysis showed that ATM inhibition or loss of
53BP1 clearly led to different defects in response to irradia-
tion (Fig. 1). Reduced ability to initiate cell cycle arrest in
response to irradiation may also translate into altered survival
kinetics of irradiated cells. To test this, we subsequently ana-
lysed clonogenic survival. To exclude that ATM inhibition
resulted in altered growth rates and thereby inﬂuenced the
results of the clonogenic survival assay upon irradiation,
MTT proliferation assays were conducted and revealed that
ATM inhibition on its own did not signiﬁcantly alter growth
rates of HeLa cells or SiHa cells (data not shown; Supporting
Information Fig. S3A). Importantly, inhibition of ATM
resulted in a dramatic reduction in clonogenic survival after
Figure 2. ATM- and 53BP1-dependent clonogenic survival in
irradiated cervical cancer cell lines. (a) C33A, CaSki, SiHa and
HeLa cells were infected with pRS control virus or pRS-53BP1
shRNA virus. Cells were plated in six-well plates and subsequently
irradiated with indicated amounts of ionising irradiation and
allowed to grow colonies. If indicated, cells were treated with
KU55933 prior to irradiation. Surviving colonies were stained. (b)
Quantification of colony numbers. If no colonies survived, a
dashed line is shown. Data are shown from three independent
experiments.
Figure 1. ATM- and 53BP1-dependent cell cycle arrest in irradiated
cervical cancer cell lines. (a) C33A, CaSki, SiHa and HeLa cells were
infected with pRS control virus or pRS-53BP1 shRNA virus. Whole-cell
lysates of puromycin-resistant polyclonal cells were obtained and
analysed with immunoblotting using indicated antibodies. (b) HeLa-
pRS, HeLa-pRS53BP1 and HeLa-pRS cells pre-treated with KU55933
were irradiated (5 Gy) and harvested at indicated time points. Cells
were fixed and stained for phospho-HistoneH3/Alexa-488 and
propidium iodide/RNAse. 1  104 events were measured by flow
cytometry, and representative DNA plots are shown. Inlays show
phospho-HistoneH3 stainings, and indicated percentages show
phospho-HistoneH3-positive cells. (c) HeLa cells infected with pRS or
pRS-53BP1 were irradiated (5 Gy) and harvested after indicated time
periods. Immunoblotting was performed with indicated antibodies. (d)
C33A, CaSki, SiHa and HeLa cells were treated as for Panel b, and
relative amounts of cells with 2 N DNA content (G1-cells) are indicated
at 24 hr after irradiation. Standard deviations of three independent
experiments are shown. (e) C33A, CaSki, SiHa and HeLa cells were
treated as for Panel b, and relative amounts of cells with phospho-
HistoneH3-positive cells at 3 hr after irradiation are indicated.
Standard deviations of three independent experiments are shown. (f)
RPE, BJ foreskin fibroblasts and HeLa cells were treated with 10 lM
KU55933 prior to irradiation. Twenty-four hours after irradiation,
apoptosis was analysed by microscopic assessment of acridine
orange staining. Representative images are indicated, and
averages of three experiments (with at least 100 cells per experiment)
are shown. Arrowheads indicate apoptotic cells. [Color figure can be
viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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irradiation, observed in all cell lines tested (Figs. 2a and 2b).
Notably, CaSki cells appeared much more sensitive to ATM
inhibition compared to other cell lines (Fig. 2b). In contrast,
loss of 53BP1 only resulted in a very moderate loss of clono-
genic survival after irradiation in all four cell lines (Figs. 2a
and 2b). As expected, loss of 53BP1 did not further sensitise
cells that were treated with ATM inhibitor (Figs. 2a and 2b).
Altogether, our results indicate a differential requirement for
ATM or 53BP1 with respect to irradiation-induced cell cycle
arrest and show that ATM inhibition dramatically radiosensi-
tises cervical cancer cells as judged by survival assays. These
results imply that the levels of ATM activity, perhaps even prior
to irradiation, may determine the effect of (chemo)radiation.
Predictive value of ATM and 53BP1 for response to
treatment
To investigate the predictive value of ATM activity for
response to irradiation in cervical cancer cells, we analysed
the levels of phospho-Ser1981-ATM before and after irradia-
tion (Fig. 3a). HeLa and SiHa cells have very low baseline
levels of phospho-ATM, in contrast to CaSki cells that have
activated ATM even prior to irradiation (Fig. 3a). Interest-
ingly, baseline amounts of phospho-ATM seem to correlate
with radioresistance, as CaSki cells were signiﬁcantly more
resistant to irradiation than HeLa and SiHa cells as observed
in clonogenic survival assays (Fig. 3b). These ﬁndings suggest
that ATM activity prior to treatment can be used as a predic-
tor of response to irradiation. To test the speciﬁcity of anti-
bodies in parafﬁn-embedded material, we analysed parafﬁn-
embedded cervical cancer cell lines irradiated in the presence
or absence of ATM inhibitors (Supporting Information Fig.
S4A). Our results showed that irradiation clearly increases
phospho-S1981-ATM levels as well as phospho-S25-53BP1
levels, a process that is completely reverted after pre-treat-
ment with ATM inhibitor KU55933 (Supporting Information
Fig. S4A). These ﬁndings indicate that phospho-S1981-ATM
Figure 3. Relationship of ATM and 53BP1 expression to locoregional disease-free survival. (a) HeLa, SiHa and CaSki cells were left untreated
or irradiated (5 Gy). Thirty minutes after irradiation, cells were lysed and immunoblotted for phospho-Ser1981-ATM and b-actin. (b) HeLa, SiHa
and CaSki cells were plated in six-well plates and subsequently irradiated with indicated amounts of ionising irradiation and allowed to grow
colonies. Surviving colonies were stained, and average colony numbers of three experiments are indicated. (c) Representative immunostaining
for p-ATM and p-53BP1 in advanced-stage cervical cancer is shown. (d) Kaplan-Meier plots of locoregional disease-free survival related to the
expression of p-ATM and p-53BP1. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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and phospho-S25-53BP1 can be detected speciﬁcally in paraf-
ﬁn-embedded cervical cancer cells and that both stainings
reﬂect ATM activity.
To investigate whether indeed ATM activity has predictive
value for response to (chemo)radiation, we examined phospho-
Ser1981-ATM [phosphorylated ATM (p-ATM)] levels in pre-
treatment cervical cancer tissues. Representative p-ATM stain-
ings in cervical cancer tissue are shown in Figure 3c (details of
staining evaluation are described in Supporting Information
Document SD1). Any positive nuclear staining (10% of in-
tensity 1) for p-ATM was observed in 344 of 349 patients
(98.6%), indicating that ATM is activated at least to some
degree in virtually all patients. High levels of p-ATM expres-
sion, however, were observed only in 183 patients (52.4%).
We analysed the expression levels of the ATM substrate
53BP1. Positive nuclear expression for 53BP1 was observed
in 100% of the tumours with similar intensity, and thus, no
statistical analysis for 53BP1 expression could be performed.
Positive nuclear phospho-S25-53BP1 [phosphorylated 53BP1
(p-53BP1)] expression, representing ATM activity, was
observed in 180 of 311 tumours (57.9%). As expected for a
direct substrate of ATM,6,10,13 a positive signal for p-53BP1
was more frequently found in tumours with high p-ATM in
comparison to negative/low p-ATM [odds ratio (OR) ¼
2.206; 95% CI ¼ 1.383–3.519; p ¼ 0.001].
We evaluated the relationship between clinicopathological
data versus p-ATM and p-53BP1 expression (Table 1). Logis-
tic regression analysis showed higher expression levels of p-
ATM in advanced stage (IIb) tumours (OR ¼ 1.851; p ¼
0.007). In addition, tumour diameter (4 cm; OR ¼ 1.848; p
¼ 0.014) and age (OR ¼ 1.005: p ¼ 0.006) were also related
to p-ATM expression. None of the clinicopathological fea-
tures showed a statistical relationship with positivity for p-
53BP1 (Table 1).
Table 1. Relationship between tumour staining for p-ATM and
p-53BP1 versus clinicopathological data
OR (95% CI) p-value
High p-ATM positive
Age 0.981 (0.968–0.994) 0.006
Stage  IIb 1.851 (1.179–2.905) 0.007
Adenocarcinoma 1.778 (0.954–3.311) 0.070
Poor differentiation 1.259 (0.799–1.983) 0.321
Lymphangio invasion 0.715 (0.389–1.314) 0.280
Tumour diameter  4 cm 1.848 (1.135–3.010) 0.014
p-53BP1 positive
Age 0.989 (0.975–1.004) 0.148
Stage  IIb 1.253 (0.786–1.996) 0.343
Adenocarcinoma 0.764 (0.407–1.434) 0.401
Poor differentiation 1.170 (0.724–1.891) 0.521
Lymphangio invasion 0.724 (0.385–1.362) 0.317
Tumour diameter  4 cm 1.118 (0.669–1.869) 0.670
Table 2. Immunostaining in relation to poor response to therapy
Univariate Multivariate1
HR (95% CI) p-value HR (95% CI) p-value
Model I
Age 1.009 (0.996–1.021) 0.164
Stage  IIb 2.412 (1.449–4.015) 0.001 2.337 (1.375–3.971) 0.002
Adenocarcinoma 1.700 (1.050–2.752) 0.031 2
Poor differentiation 1.009 (0.669–1.521) 0.967
Lymphangio invasion 0.946 (0.533–1.681) 0.851
Tumour diameter  4 cm 2.210 (1.308–3.735) 0.003 2
High p-ATM positive 1.817 (1.191–2.772) 0.006 1.650 (1.076–2.528) 0.022
p-53BP1 positive 1.083 (0.690–1.702) 0.728
Model II OR (95% CI) p-value OR (95% CI) p-value
Age 1.014 (0.991–1.037) 0.232
Stage  IIb 2.966 (1.292–6.810) 0.010 3.462 (1.309–9.156) 0.012
Adenocarcinoma 4.621 (1.888–11.311) 0.001 3.822 (1.430–10.214) 0.007
Poor differentiation 0.852 (0.413–1.758) 0.665
Lymphangio invasion 1.630 (0.694–3.827) 0.262
Tumour diameter  4 cm 3.046 (1.196–7.760) 0.020 2
High p-ATM positive 2.567 (1.243–5.299) 0.011 2.336 (1.042–5.237) 0.039
p-53BP1 positive 0.659 (0.305–1.423) 0.289
1Multivariate analysis adjusted for treatment modality. 2Not in final step of multivariate analysis.
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p-ATM and p-53BP1 in relation to response to
(chemo)radiation and survival
To analyse the relationship of p-ATM and p-53BP1 protein
expression with response to (chemo)radiotherapy, two mod-
els were used as described previously.22 In Model I, wherein
treatment response is based on locoregional disease-free sur-
vival, 364 patients (97.1%) could be analysed. The evaluation
of locoregional disease-free survival was used as it is a rele-
vant measurement of local effects induced by (chemo)radia-
tion, which induces ATM pathway activation. In this model,
high p-ATM was related to poor locoregional disease-free
survival in univariate Cox regression analysis [hazard ratio
(HR) ¼ 1.817; p ¼ 0.006] as well as in multivariate analysis
(HR ¼ 1.650; p ¼ 0.022), whereas p-53BP1 expression was
not related (Table 2). Figure 3d depicts locoregional disease-
free survival in relation to high p-ATM and p-53BP1 expres-
sion. In this analyses, the log-rank p-value for high p-ATM
expression was p ¼ 0.003. To further strengthen our hypoth-
esis that high levels of p-ATM are associated to the response
to (chemo)radiotherapy, we evaluated response-to-treatment
in a second model. In Model II, we separated our data in
two subsets of patients with the highest contrast in treatment
response (see Patients and Methods section in Supporting In-
formation Document SD1).22 In this model, a statistical sig-
niﬁcant association between high p-ATM and poor response
to treatment was found in univariate logistic regression anal-
ysis (OR ¼ 2.567; p ¼ 0.011) as well as in multivariate analy-
sis (OR ¼ 2.336; p ¼ 0.039) (Table 2). p-53BP1 was not
related to response to (chemo)radiation. After selection of
these extreme groups, the relationship of p-ATM with poor
response-to-treatment was even stronger compared to Model
I. These data indicate that pre-treatment ATM activity levels,
but not phosphorylation status of 53BP1, is relevant for the
response to (chemo)radiation in patients with cervical cancer.
Finally, we analysed the expression of p-ATM and p-
53BP1 in relation to disease-speciﬁc survival. During follow-
up, 201 of 375 201/375 ¼ 54%) patients died. In 155/201 ¼
77% of these patients, death was related to cervical cancer
(disease-speciﬁc survival). In line with our results described
above, no relationships were observed between p-53BP1
expression and disease-speciﬁc survival. However, we found
that high p-ATM expression was related to worse disease-
speciﬁc survival (HR ¼ 1.418; p ¼ 0.038) in univariate analy-
sis (Table 3), again underscoring a role for ATM activity in
cervical cancer behaviour.
Discussion
Our study shows a critical role for active ATM in the
response of cervical cancer to irradiation, both in cervical
cancer cell lines as well as in patients with cervical cancer
treated with (chemo)radiation. Our in vitro studies indicate
that cervical cancer cells, even in the presence of HPV E6
expression, which blocks p53 function, still undergo a robust
G1 cell cycle arrest in response to irradiation. HPV-positive
cervical cancer cells require both ATM activity and the pres-
ence of 53BP1 for induction of this irradiation-induced G1
arrest. In addition, ATM, but not 53BP1, is required for
induction of a G2/M cell cycle arrest.
The requirements for ATM and 53BP1 for induction of an
irradiation-induced G1 arrest are likely explained by residual
p53 function in HPV-positive cervical cancer cells, which most
often carry wild-type alleles of p53.27 Both ATM and 53BP1
have been described to regulate p53 function. Although ATM
has been extensively described to directly regulate p53,4 a role
for 53BP1 in the regulation of p53 is controversial. 53BP1 was
initially demonstrated to bind p53 and promote p53 activ-
ity12,28; however, T-cells from 53BP1/ mice still showed ro-
bust irradiation-induced p53 responses.29 Our results indicate
that 53BP1 is required for p53 function, albeit in a background
with compromised p53 levels. However, in HPV-positive cervi-
cal cancer cells this does not appear to have functional conse-
quences, since 53BP1-depletion did not dramatically alter clon-
ogenic survival of cell lines after irradiation. Moreover, 53BP1-
phosphorylation was not associated with response to
(chemo)radiation.
In our study, the inhibition of ATM in cervical cancer
cells interfered with the irradiation-induced G1 and G2/M
cell cycle arrest, in line with the loss of checkpoint function
in cells from patients with AT.4,7,30 ATM inhibition
Table 3. Immunostaining of p-ATM and p53BP1 in relation to disease-specific survival
Disease-specific survival
Univariate Multivariate1
HR (95% CI) p-value HR (95% CI) p-value
Age 1.003 (0.993–1.013) 0.520
Stage  IIb 2.170 (1.463–3.217) <0.001 1.907 (1.249–2.911) 0.003
Adenocarcinoma 1.507 (0.999–2.273) 0.050 2
Poor differentiation 1.211 (0.873–1.681) 0.251
Lymphangio invasion 1.125 (0.726–1.744) 0.597
Tumour diameter 4 cm 1.967 (1.308–2.959) 0.001 1.640 (1.068–2.519) 0.024
High p-ATM positive 1.418 (1.019–1.972) 0.038 2
p-53BP1 positive 0.819 (0.576–1.165) 0.267
1Multivariate analysis adjusted for treatment modality. 2Not in final step of multivariate analysis.
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furthermore severely decreased clonogenic survival for all
tested cervical cancer cell lines, indicating that cervical cancer
cells heavily depend on the ATM signalling axis for survival
after irradiation. Interestingly, when ATM was inhibited in
irradiated non-transformed RPE cells or BJ foreskin ﬁbro-
blasts, no induction of apoptosis was observed, in contrast to
the apoptotic effects of ATM inhibition on HeLa cells, imply-
ing that a therapeutic window for ATM inhibition may be
present. Further research, however, is required to investigate
the long-term toxicity proﬁle of ATM inhibition in normal
cells. In addition, investigation of the combined effects of
radiotherapy and ATM inhibition in normal tissues are
needed to further establish ATM as a therapeutic target for
radiosensitisation.
These observations, as well as our ﬁndings that high base-
line levels of active ATM correlate to increased clonogenic
survival after irradiation, suggest that high levels of activated
ATM levels are beneﬁcial for cervical tumour cell survival.
Previously, it has been acknowledged that the ability to repair
therapy-induced DNA damage counteracts the efﬁcacy of
therapy in a number of tumour types. For instance, high
expression levels of the repair enzyme MGMT counteracts
the effects of alkylating agents and predicts poor prognosis in
gliomas.31 Conversely, low expression level of the DNA dam-
age repair gene ERCC1 correlates with prolonged survival of
patients with non-small cell lung cancer.32
To analyse whether activation status of ATM was also
related to therapy outcome, we assessed the expression of p-
ATM and the expression of p-53BP1. To our knowledge, this
is the ﬁrst time that ATM and 53BP1 have been assessed by
immunohistochemistry in their activated phosphorylated state
in a large, well-documented and consecutive series of patients
with cervical cancer primarily treated with (chemo)radiation.
Our data suggest that high expression levels of p-ATM are
related to poor locoregional disease-free survival. Currently,
only very limited data concerning ATM and 53BP1 expres-
sion in relation to response to (chemo)radiation and survival
in other malignancies is present. The few studies that investi-
gated ATM expression show an ambiguous picture. In
patients with pancreatic cancer, ATM expression in their
tumours was not a prognostic factor.33 In contrast, expression
of ATM in colorectal cancer was related to good survival in a
large series of patients, although only a subset was treated
with genotoxic therapy.34 In oesophageal cancer and early
stage breast cancer, ATM expression did not predict response
to therapy.35,36
Our results show that expression of p-ATM was related to
response-to-treatment, whereas expression of p-53BP1 was
not related. Importantly, our clinical data were in line with
our cell line data, in which we show that 53BP1 inhibition
did not affect clonogenic survival upon irradiation. Although
predictive roles for 53BP1 were unknown in cervical cancer,
high expression levels of 53BP1 were associated with poor
responses to cisplatin-based therapy in lung cancer.37 In anal-
ogy, 53BP1 was overexpressed speciﬁcally in those ovarian
tumours that showed resistance to paclitaxel/carboplatin-
based therapy.38 In addition, 53BP1 was frequently lost in he-
reditary breast cancers, where it was suggested to relieve the
genomic instability caused by BRCA1 loss.17 The diversity of
these results could be explained by differences in treatment
modality between and even within these studies. Moreover,
our study focussed predominantly on the activation status of
both proteins, rather than expression levels only. Finally, car-
cinogenesis of cervical cancer is fundamentally different from
that of the tumour types under study in the latter reports. It
may very well be that early inactivation of p53 through HPV
infection account for differences in prognostic factors, espe-
cially those functioning within the DDR.
ATM is activated in response to chemoradiation. The rela-
tively high levels of p-ATM that we observed in our therapy-
naive cervical tumour specimens could represent continuous
activation of the ATM-regulated DDR as a result of deregu-
lated proliferation, as also reported for other tumour
types.39,40 Alternatively, elevated levels of p-ATM prior to
(chemo)radiation may point at DNA damage-independent
functions of ATM, such as the recently reported role for
ATM in sensing oxidative stress levels.41
In summary, on the basis of our results, high phospho-
ATM levels is an independent predictor for poor response in
cervical cancer. In addition, targeting ATM kinase activity
could be an interesting therapeutic option to sensitise tumour
cells for (chemo)radiation in patients with cervical cancer
who have high tumour levels of active ATM before start of
(chemo)radiotherapy. Our data, in line with other reports,
show that inhibition of ATM by targeted drug application
results in enhanced sensitivity to radiotherapy,23,42,43 recapit-
ulating the radiosensitivity phenotypes of cells of patients
with AT.4,7,30,44 Moreover, in short-term in vitro assays, a
therapeutic window for ATM inhibition appears to be pres-
ent for ATM inhibition when the toxicity to non-cancer cells
is taken into account. This differential sensitivity to ATM in-
hibition may be related to HPV-dependent rewiring of the
cell cycle machinery. Other investigations have reported
enhanced radiosensitivity by inhibition of ATM in several
malignancies.45–49 Although ATM inhibitors are still in pre-
clinical development, our study suggests relevance of ATM-
targeted agents and warrants a further assessment of ATM
inhibition as a (chemo)radiosensitising treatment in patients
with advanced-stage cervical cancer. However, besides
increased radiosensitivity, patients with AT also show
increased cancer development,4,7,44 and therefore, prolonged
ATM inhibition should be avoided. In clinical settings, only a
scenario in which short-term ATM inhibition can be com-
bined with the local induction of DNA damage seems feasi-
ble. In this respect, it is very relevant that reversible ATM
inhibitors have recently been described and that transient
ATM inhibition was shown to reach radiosensitising effects
in cancer cells.47
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